Targeted Cancer Therapy Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520.

Slides:



Advertisements
Similar presentations
Ulrik Lassen MD, PH.D Phase 1 Unit
Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program
Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
Strategies to overcome resistance in NSCLC with driver mutations
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
Biol518 Lecture 2 HTS and Antibiotic Drug Discovery.
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Introduction to Glioblastoma Chris Plaisier Introduction to Systems Biology Course Institute for Systems Biology.
Precision Medicine: From stratified therapies to personalized therapies Fabrice ANDRE Institut Gustave Roussy Villejuif, France.
In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Pharmacogenomics and personalized medicines Jean-Marie Boeynaems
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Vs. home.ccr.cancer.gov Personalized medicine-The goal.
Genetics-multistep tumorigenesis genomic integrity & cancer Sections from Weinberg’s ‘the biology of Cancer’ Cancer genetics and genomics Selected.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
“CRISPR genome editing” Precise gene regulation/modification using the simple CRISPR/Cas9 system Thank you. Nucleeases will be used as a new tool that.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Dose Response 100% 50% 0% IC50, EC50 Dose response curve.
Optimization of personalized therapies for anticancer treatment Alexei Vazquez The Cancer Institute of New Jersey.
1 Jin-Soo Kim Dept. of Chemistry, Seoul National Univ. Center for Genome Engineering, Institute for Basic Science Genome Editing: Challenges and Opportunities.
Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
Lecture-7 Genome editing CRISPR
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Cancer Therapies DNA microarrays are used to assess the relative expression of thousands of genes simultaneously—relative expression means that.
Samuel Aparicio, B.M., B.Ch., Ph.D., and Carlos Caldas, M.D.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
Immuno and Epigenetic Therapies Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520.
EML4-ALK non-small cell lung cancer
Population sequencing using short reads: HIV as a case study Vladimir Jojic et.al. PSB 13: (2008) Presenter: Yong Li.
CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.
Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520
Samsung Genome Institute Samsung Medical Center
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
advanced lung adenocarcinoma subtype
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1 Mark M
Unità Clinica di Diagnostica Istopatologica e Molecolare
New Patient Journeys in Non-small cell lung cancer
Updates in Lung Cancer: Insights From Vienna
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
C. Allison Stewart, Lauren Averett Byers  Cancer Cell 
WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.
Implementing Genome-Driven Oncology
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors  Hsin-Yi Wang, MD  Journal of Thoracic.
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Fig. 1. scRNA-seq applications in cancer medicine.
Personalized Medicine: Patient-Predictive Panel Power
C. Allison Stewart, Lauren Averett Byers  Cancer Cell 
Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.
Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment
Strong parallelism in mutated genes defines adaptations to the environment of CF patient lungs. Strong parallelism in mutated genes defines adaptations.
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers  Morana Vojnic, MD, Daisuke Kubota, MD, PhD, Christopher.
Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.
Single-cell analyses to tailor treatments
Combined inhibition of coamplified RTKs is required for response.
No single ALK mutations confer high-level resistance to lorlatinib.
Updates in Best Practices in Non-Small Cell Lung Cancer
Presentation transcript:

Targeted Cancer Therapy Xiaole Shirley Liu STAT115, STAT215, BIO298, BIST520

Hallmarks of Cancer 2

Mutually Exclusivity and Co-occurrence Most cancers have >=2 sequential mutations developed over many years. Mutations in different pathways can co-occur in the same cancer, whereas those in the same pathway are rarely mutated in the same sample. 3

Why Tumor Sequencing videohttp:// Chemotherapy vs targeted therapy –Chemotherapy: non-specific cytotoxic drugs, mostly affecting dividing cells, mostly intravenous –Targeted: inhibit a specific target, less toxic to normal cells, mostly oral Many major cancer hospitals in US started patient tumor sequencing The hope to identify the correct targeted therapy 4

Cancer Profiles vs Treatment “The Difficulty is going to be figuring out how to use the information to help people rather than to just catalogue lots and lots of mutations.” – Bert Voglestein, John Hopkins University Chemotherapy vs targeted therapy –Chemotherapy: non-specific cytotoxic drugs, mostly affecting dividing cells, mostly intravenous –Targeted: inhibit a specific target, less toxic to normal cells, mostly oral videohttp:// 5

6 ~479 genes Limited Number of Cancer Driver Genes Half Druggable

ALK Inhibitors ALK normally functions in the brain First rearrangement in lung cancer discovered 2007 in Japan Upstream of multiple cancer pathways 2010 starting clinical trials on ALK inhibitor 2011 FDA approved crizotinib 7

8

Testing on Patients Takes Lots of Time and Money Can we do this faster? 9

Cell Line Drug Screens CGP: 138 drugs on 727 cell lines CCLE: 24 drugs on 1,036 cell lines 10

Targeting a Cancer Pathway Why bother screening if we know the target of a drug? E.g. doesn’t ALK inhibitor inhibit ALK? 11

Cell Line Drug Screens Cell lines: –Expression –Mutations –Drug sensitivity measure: IC50, half maximal inhibitory concentration (IC 50 ) How to find expression or mutation biomarkers for drug response? 12

Drug Response BioMarkers Mutations Expression 13 AHR expression high or low on MEK inhibitor (PD )

Instead of Drug-Focused, Can we Test Tumor-Specific Therapies? 14

Genome-wide Loss of Function Screens Get rid of a gene (DNA or RNA) in a cell See how it influences one specific cancer cell as compared to other cells (specificity) Can we do this in high throughput? 15

Profile Cancer Cell Vulnerability 16

CRISPR-Cas: Bacterial Adaptive Immune System Clustered regularly interspaced short palindromic repeats 17

CRISPR-Cas9 Knockout Guide RNA allows Cas9 to make ds breaks at specific genomic locations in the genome Repairs on exonic breaks create loss-of function gene knockouts 18

Genome-Wide CRISPR-Cas9 Knockout Screen Positive selection: –Guide abundance up –Knockout genes make cells grow faster Negative selection: –Guide abundance down –Knockout genes make cells grow slower Identify cell-specific and condition-specific essential genes and biomarkers of drug response & resistance 19 Shalem et al, Science, 2014

Genome-Wide CRISPR/Cas9 Knockout Screens Each vector contains a guide sequence (sgRNA) knock out a gene (influence DNA) instead of knock down expression (influence RNA) Detection through sequencing instead of bar- coded arrays 20 Shalem et al, Science 2014; Wang et al, Science 2014

Analyzing Ge-LoF Screen Data How to normalize raw data? What if one shRNA / sgRNA doesn’t work How to identify key genes if we have multiple shRNAs / sgRNA per gene? 21

Targeted Therapy ENO1 and ENO2 parallel pathway Glioblastoma tumors with ENO1 deletion (5%) is sensitive to ENO2 inhibition 22

Drug Resistance 23

Targeted Therapy I AR and prostate cancer Antiandrogen resistance Mutation on AR LBD ERG expands AR cistrome GR over expression EMT Luminal to basal

Targeted Therapy II EGFR and non-small cell lung cancer EGFR inhibitor resistance T790M MET amplification HGF production PI3K mutation SCLC

Similarities Anti AR resistance –Mutation on AR LBD –ERG expands AR cistrome –GR over expression –EMT –Luminal to basal Anti EGFR resistance –T790M –HGF production –MET amplification –PI3K mutation –SCLC

Resistance Mechanism Is resistance developed before or after drug treatment? Point mutation rate: 10^ -9 Minority of resistance clones get selected for clonal expansion Possible ways to evade drug?

Tumor Heterogeneity

Mathematical Models of Resistance Use cell data to estimate the parameters Test agreement between simulation and observation Suggest full dose neo-adjuvant chemotherapy before surgery Haeno et al, Cell 2012

How to Find Resistance Mechanisms Cell lines? CCLE and CGP drug screens –Drug A works for cancers with Gene A mutation –Identify informative Gene B whose expression or mutation influence cancer response to drug A –If Gene B is also drugable, then can find combination A & B for tumor subsets

How to Find Resistance Mechanisms Cell lines? CCLE and CGP drug screens shRNA or sgRNA screens –Treat resistant cell with drug or no drug –Does ko/kd of a gene make the cell more / less sensitive?

Effective Drug Treatment A perfect recipe for certain treatment failure: sequential therapy. Successful combination therapy must force the cancer to make at least two mutations steps. Is current FDA clinical trials unethical?

Summary Use expression and mutations as biomarkers to predict drug response Use high throughput screening in cell lines to identify specific targets essential for cancer cells Resistance to targeted therapy is extremely prevalent, and many present in initial tumor Tumor heterogeneity and cancer evolution Effective treatment: neo-adjuvant and combination therapy 33

Acknolwedgement John Pack James Lechner Alex Chenchik Natalia Kamarova Haiyun Wang 34